Changes in high-density lipoprotein and homeostasis model assessment of insulin resistance in medicated schizophrenic patients and healthy controls.
This study intended to simultaneously investigate the relationships between high-density lipoprotein (HDL) and homeostasis model assessment of insulin resistance (HOMA-IR) in medicated schizophrenic patients vs healthy controls. During a 1-year period, we recruited 37 medicated schizophrenic patients and 30 healthy controls. Metabolic syndrome-related biomarkers including insulin and lipid profiles were enzymatically determined. An analysis of covariance (ANCOVA) with BMI adjustment revealed that the patients had significantly lower HDL levels than the healthy controls (p = 0.017). ANCOVA with age adjustment revealed that the patients had significantly higher fasting insulin levels than the healthy controls (p = 0.034). In addition, in comparison with the healthy controls, the patients had higher mean serum levels of triglycerides, low-density lipoprotein, and total cholesterol as well as higher HOMA-IR values. However, there were no significant differences in any marker in the ANCOVA analysis after adjustment for age or BMI. We found lower HDL and higher insulin levels in medicated schizophrenic patients than in healthy controls.